Acute myocardial infarction Market: Epidemiology, Therapies, Companies, DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative

Acute myocardial infarction therapies, such as LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others, are expected to boost the Acute myocardial infarction Market in the upcoming years.

DelveInsight has launched a new report on "Acute myocardial infarction - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Acute myocardial infarction, historical and forecasted epidemiology as well as the Acute myocardial infarction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Acute myocardial infarction market report @ https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Acute myocardial infarction Market Report:

The Acute Myocardial Infarction (AMI) market in the 7MM is projected to be around USD 1,600 million in 2023, with a notable compound annual growth rate (CAGR) expected during the forecast period. Among the 7MM countries, the United States is anticipated to dominate the AMI market, making up about 75% of the overall market in 2023.
The total number of AMI incident cases in the 7MM was estimated to be approximately 1,468,400 in 2023, with the United States reporting the highest number of cases.
With the FDA approval of AGEPHA Pharma's LODOCO, patients with residual inflammatory risk now have an FDA-approved treatment specifically aimed at reducing cardiovascular disease risk by targeting inflammatory pathways involved in major cardiac events.
New-generation platelet antagonists like Zalunfiban and selatogrel offer exciting potential, with easy subcutaneous injection administration at first medical contact in patients with STEMI.
The dynamics of the AMI market are expected to evolve due to advancements in diagnostic methods, increased disease awareness, and rising global healthcare spending. Leading companies such as Idorsia Pharmaceuticals, Viatris, Recardio, Amgen, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CeleCor Therapeutics, Kancera, CellProthera, and BioCardia are advancing their lead candidates through clinical development stages, poised to significantly influence the AMI market during the 2024-2034 forecast period.
In 2023, the United States is estimated to have approximately 822,800 new cases of Acute Myocardial Infarction (AMI), with this number expected to rise by 2034.
Japan recorded about 45,700 cases of STEMI and 34,500 cases of NSTEMI in 2023.
In the EU4 countries and the UK, there were around 930,900 male cases and 537,500 female cases of Acute Myocardial Infarction in 2023.
Among the total AMI incident cases, NSTEMI is expected to account for a higher number than STEMI, with an estimated 607,300 NSTEMI cases in the United States in 2023.
In April 2024, the FDA granted Breakthrough Device Designation to PMcardio's STEMI AI ECG Model. This artificial intelligence-based platform analyzes 12-lead ECGs to detect acute ST-elevation myocardial infarction (STEMI) and other cardiovascular conditions within seconds. The designation aims to expedite the development and review of this tool, potentially enhancing early diagnosis and treatment of AMI.
Key Acute myocardial infarction companies such as Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others are evaluating new drugs for Acute myocardial infarction to improve the treatment landscape.
Promising Acute myocardial infarction therapies include LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others.

Acute myocardial infarction Overview

Acute Myocardial Infarction (AMI), also known as a heart attack, is a critical medical condition that occurs when blood flow to a part of the heart muscle is abruptly blocked. This blockage typically results from a clog in one of the coronary arteries, which supply oxygen and nutrients to the heart.

AMI is a common manifestation of cardiovascular disease (CVD) in older individuals, with an elevated risk of death, complications, and increased healthcare costs. Currently, there are several effective treatments available after a myocardial infarction, with guidelines recommending lifelong preventive therapy using medications such as beta-blockers, ACE inhibitors or angiotensin II receptor blockers, acetylsalicylic acid, and statins, unless contraindicated.

Acute myocardial infarction Market Outlook

Several prominent companies are actively researching their drugs for Acute Myocardial Infarction, including Idorsia Pharmaceuticals, Viatris, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Amgen, Arrowhead Pharmaceuticals, Faraday Pharmaceuticals, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, Recardio, CeleCor Therapeutics, Kancera, CellProthera, BioCardia, Mesoblast, and others. Detailed market size information by country and therapy is provided below.

In the 7MM region, the United States holds the largest market share for Acute Myocardial Infarction in 2023. On the other hand, Spain represented the smallest market size for AMI among the 7MM countries, at approximately USD 25 million.

Among the emerging therapies for Acute Myocardial Infarction expected to launch during the forecast period, Ziltivekimab is projected to generate the highest revenue by 2034.

Discover how the Acute myocardial infarction market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute myocardial infarction marketed drugs

LODOCO (colchicine): AGEPHA Pharma
TNKase (tenecteplase): Genentech

Acute myocardial infarction Emerging Drugs
Dutogliptin: Recardio
Selatogrel: Idorsia Pharmaceuticals and Viatris

Scope of the Acute myocardial infarction Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute myocardial infarction Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and others
Key Acute myocardial infarction Therapies: LODOCO (colchicine), TNKase (tenecteplase), Dutogliptin, Selatogrel, and others
Acute myocardial infarction Therapeutic Assessment: Acute myocardial infarction current marketed and Acute myocardial infarction emerging therapies
Acute myocardial infarction Market Dynamics: Acute myocardial infarction market drivers and Acute myocardial infarction market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute myocardial infarction Unmet Needs, KOL's views, Analyst's views, Acute myocardial infarction Market Access and Reimbursement

To know what's more in our Acute myocardial infarction report, visit https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute myocardial infarction Market Report:
Acute myocardial infarction market report covers a descriptive overview and comprehensive insight of the Acute myocardial infarction Epidemiology and Acute myocardial infarction market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Acute myocardial infarction market report provides insights into the current and emerging therapies.
The Acute myocardial infarction market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Acute myocardial infarction market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute myocardial infarction market.

Got queries? Click here to know more about the Acute myocardial infarction market Landscape https://www.delveinsight.com/sample-request/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute myocardial infarction Patient Share (%) Overview at a Glance
5. Acute myocardial infarction Market Overview at a Glance
6. Acute myocardial infarction Disease Background and Overview
7. Acute myocardial infarction Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute myocardial infarction
9. Acute myocardial infarction Current Treatment and Medical Practices
10. Unmet Needs
11. Acute myocardial infarction Emerging Therapies
12. Acute myocardial infarction Market Outlook
13. Country-Wise Acute myocardial infarction Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute myocardial infarction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute myocardial infarction Market Outlook 2034 https://www.delveinsight.com/report-store/acute-myocardial-infarction-ami-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute myocardial infarction Pipeline Insights, DelveInsight

"Acute myocardial infarction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute myocardial infarction market. A detailed picture of the Acute myocardial infarction pipeline landscape is provided, which includes the disease overview and Acute myocardial infarction treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.